(Q38359027)

2 September 2017

title

Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways (English)

1 reference

2 September 2017

1 reference

18

Kohjiro Ueki

1 reference

2 September 2017

19

Takashi Kadowaki

1 reference

2 September 2017

15

Ryozo Nagai

1 reference

2 September 2017

Taku Watanabe

1

1 reference

2 September 2017

Naoto Kubota

2

1 reference

2 September 2017

Mitsuru Ohsugi

3

1 reference

2 September 2017

Tetsuya Kubota

4

1 reference

2 September 2017

Iseki Takamoto

5

1 reference

2 September 2017

Masato Iwabu

6

1 reference

2 September 2017

Motoharu Awazawa

7

1 reference

2 September 2017

Hisayuki Katsuyama

8

1 reference

2 September 2017

Chiaki Hasegawa

9

1 reference

2 September 2017

Kumpei Tokuyama

10

1 reference

2 September 2017

Masao Moroi

11

1 reference

2 September 2017

Kaoru Sugi

12

1 reference

2 September 2017

Toshimasa Yamauchi

13

1 reference

2 September 2017

Tetsuo Noda

14

1 reference

2 September 2017

Yasuo Terauchi

16

1 reference

2 September 2017

Kazuyuki Tobe

17

1 reference

2 September 2017

language of work or name

English

0 references

publication date

13 November 2008

1 reference

Journal of Biological Chemistry

2 September 2017

published in

1 reference

2 September 2017

volume

284

1 reference

2 September 2017

issue

3

1 reference

2 September 2017

page(s)

1803-1812

1 reference

Obesity wars: molecular progress confronts an expanding epidemic

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Leptin-regulated endocannabinoids are involved in maintaining food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

The endocannabinoid system and its therapeutic exploitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Cannabinoid physiology and pharmacology: 30 years of progress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Adipose tissue: from lipid storage compartment to endocrine organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Disruption of adiponectin causes insulin resistance and neointimal formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

The AMP-activated protein kinase pathway--new players upstream and downstream.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

The anti-obesity effect of rimonabant is associated with an improved serum lipid profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

The hormone resistin links obesity to diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Adipose tissue as an endocrine organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Drug treatments for obesity: orlistat, sibutramine, and rimonabant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Therapeutic potential of cannabis in pain medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M807120200

21 January 2018

Identifiers

DOI

10.1074/JBC.M807120200

1 reference

2 September 2017

1 reference